On August 22, Boston Scientific rose 3.01% in regular trading, trading at $50.85 per share, with turnover of $775 million. The rally was driven by two product approvals in China that broadened the company's local manufacturing footprint.

Specifically, Boston Scientific's next-generation FARASTAR cardiac pulsed field ablation system and Rezum EVO prostate thermal vapor treatment device both received approval from China's National Medical Products Administration. The FARASTAR system set a record as the company's fastest-approved locally manufactured device in China, with the review cycle shortened by approximately 1.5 months versus prior comparable projects. China also became one of the first markets globally to approve the Rezum EVO device. Both products will be manufactured at Boston Scientific's Shanghai Lingang factory, expanding the facility's scope from high-end interventional consumables to complex device platforms.

The approvals provided stage-specific repair momentum for shares that had been under sustained pressure following a full-year guidance cut in late July, when management projected mid-to-high single-digit year-over-year declines in Watchman revenue for the second half, prompting multiple investment banks to significantly lower their price targets.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)